Holen Sie sich die Stockscreener-App
324.30
0.38%
-1.24
Vorhandelsmarkt:
322.62
-1.68
-0.52%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$325.54
Offen:
$327.42
24-Stunden-Volumen:
2.38M
Relative Volume:
0.91
Marktkapitalisierung:
$174.63B
Einnahmen:
$35.89B
Nettoeinkommen (Verlust:
$7.01B
KGV:
25.07
EPS:
12.9352
Netto-Cashflow:
$11.54B
1W Leistung:
-1.78%
1M Leistung:
+2.06%
6M Leistung:
+9.83%
1J Leistung:
+20.03%
1-Tages-Spanne:
$319.79
$327.75
1-Wochen-Bereich:
$319.79
$343.05
52-Wochen-Spanne:
$261.43
$346.38
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Vergleichen Sie AMGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
324.30 | 175.30B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,077.19 | 967.52B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
213.65 | 505.28B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
220.75 | 388.90B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
141.61 | 272.12B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.26 | 271.01B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Decliners Report: Why Amgen Inc stock could rally in 20252025 Breakouts & Breakdowns & Weekly Top Performers Watchlists - moha.gov.vn
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman - Benzinga
Ro partners with Amgen to study barriers to obesity care, GLP-1 access - marketscreener.com
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance - FinancialContent
Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage - marketscreener.com
Amgen (AMGN) Reveals Promising Results from MariTide Phase 2 Stu - GuruFocus
Amgen Inc. $AMGN Shares Acquired by PKO Investment Management Joint Stock Co - MarketBeat
Nordea Investment Management AB Acquires 22,465 Shares of Amgen Inc. $AMGN - MarketBeat
Trickle of Data On Amgen’s MariTide Hints At Potential Of Lower Maintenance Dosing - Citeline News & Insights
Amgen to announce data on obesity drug MariTide at healthcare conference - WNWN-FM
Amgen Inc. $AMGN Shares Bought by Citizens Financial Group Inc. RI - MarketBeat
Amgen says MariTide helped trial patients maintain weight loss - The Mighty 790 KFGO
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules - BioSpace
Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event - MarketBeat
Amgen’s MariTide Patients Maintain Weight Loss for Two Years - Bloomberg.com
Amgen's Maritide: A Breakthrough in Diabetes Management - Devdiscourse
Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight - TradingView — Track All Markets
Key Executive Transition from Amgen (AMGN) to BioMarin - GuruFocus
Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims - Bloomberg Law News
Lobbying Update: $37,500 of AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Inc. $AMGN Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Meeder Asset Management Inc. Purchases 27,584 Shares of Amgen Inc. $AMGN - MarketBeat
Tema Etfs LLC Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
First Horizon Corp Takes Position in Amgen Inc. $AMGN - MarketBeat
Amgen Buys U.K. Biotech Company - Los Angeles Business Journal
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen (AMGN) Investors - simplywall.st
Amgen Stock Holds Its Ground: What The Latest Price Action, Ratings and Pipeline Signals Mean For In - AD HOC NEWS
Amgen stock slides into weekend as JPMorgan healthcare conference looms - TechStock²
Nepsis Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reassess Amgen (AMGN) After Its 28% One Year Share Price Gain? - Yahoo Finance
Amgen to acquire Dark Blue for cancer drug DBT 3757 - BioXconomy
State of Alaska Department of Revenue Sells 3,034 Shares of Amgen Inc. $AMGN - MarketBeat
Oregon Public Employees Retirement Fund Buys 15,172 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Nova R Wealth Inc. - MarketBeat
The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8% - Investing.com
Amgen (NASDAQ:AMGN) Stock Rating Upgraded by UBS Group - MarketBeat
Amgen Inc. $AMGN Shares Bought by Ferguson Wellman Capital Management Inc. - MarketBeat
Amgen Inc. (NASDAQ:AMGN) aligns with nasdaq composite life sciences - Kalkine Media
Can Amgen Inc. stock rebound after recent weaknessQuarterly Earnings Report & Technical Pattern Based Signals - ulpravda.ru
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
How Amgen Inc. stock valuations compare to rivalsWeekly Profit Report & Growth Oriented Trading Recommendations - ulpravda.ru
Amgen (AMGN) Valuation Check After DISCO Oncology Deal And Fresh Analyst Optimism - simplywall.st
Amgen (NASDAQ:AMGN) Price Target Raised to $319.00 at Truist Financial - MarketBeat
Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating - MarketScreener
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan - TipRanks
Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? - Yahoo Finance
Amgen acquires British Dark Blue Therapeutics for USD 840m - medwatch.com
SG Americas Securities LLC Has $79.95 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by HB Wealth Management LLC - MarketBeat
Evotec benefits from Dark Blue acquisition by Amgen - European Biotechnology Magazine
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):